Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab Vedotin in Metastatic or Recurrent Squamous Cell Carcinoma of the Vulva
NCT07672782Phase 2Not yet recruiting
- Sponsor
- GOG Foundation
- Start
- Nov 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 2 trial of tisotumab vedotin in vulvar cancer, sponsored by GOG Foundation. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tisotumab vedotin
03
Conditions
vulvar cancer
Beyond the preview
Go deeper on NCT07672782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07672782.